MedMira and Swiss Partner Vitest Sign Private Label Agreement for Africa

About this update from Medmira Inc.

[{"type":"text","content":"\n\n\n\nHALIFAX, March 10 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and\nsolutions, announced today that it is has established a private label\npartnership with Vitest AG (Vitest). Vitest, an established private label\npartner of MedMira, plans to market and sell MedMira rapid HIV tests in Africa\nunder the Vitest brand. This partnership will increase the availability of\nquality rapid HIV tests in Africa, a market where an urgent need for testing\nexists, with an estimated 22 million people infected with HIV and nearly 2\nmillion newly infected each year. (www.unaids.org)\n\n\n"MedMira and Vitest are coming together to respond to a growing need and\nto deliver, what we believe will be the highest quality and most superior\nrapid HIV test available in the African market," said Dr. Jörg-Michael\nHollidt, CEO, Vitest AG. "The collaboration between our two companies enables\nus to deliver quickly and efficiently a high quality, world class diagnostic\nsolution with the flexibility to meet the varied needs of public health and\nprivate company testing programs in Africa."\n\n\nThe partnership enables each company to bring their core skills and focus\ntogether to achieve success in complex and highly competitive developing\nmarkets such as Africa. Under the terms of the agreement, MedMira will\nmanufacture its complete line of rapid diagnostics, which includes HIV,\nhepatitis and multiple tests built on the Company's patented and award-winning\nrapid flow-through technology platform, for Vitest to market and sell through\nvarious channels in Africa, including public health tenders and private\ncompany-sponsored programs.\n\n\n"We know that Africa is where one of the greatest testing needs exists\nand we now have the right partner in Vitest and the infrastructure in place to\nserve this market profitably," said Hermes Chan, CEO, MedMira Inc. "Our newly\noutsourced manufacturing capabilities will enable us to meet the volume and\npricing demands of this highly competitive, price-driven market. We look\nforward to working closely with Vitest to establish a firm position in Africa\nfor the MedMira/Vitest products."\n\n\nChan continued, "By integrating our efforts we can successfully meet the\npri...

More updates from Medmira Inc.